Your browser doesn't support javascript.
loading
Molecular landscape of proliferative verrucous leukoplakia: a systematic review.
Nissanka-Jayasuriya, Eranga H; Fenton, Tim R; Rose-Zerilli, Matthew J J.
Afiliación
  • Nissanka-Jayasuriya EH; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Histopathology, William Harvey Hospital, East Kent Hospitals University NHS Trust, Ashford, Kent, UK. Electronic address: e.nissanka-jayasuriya@nhs.net.
  • Fenton TR; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; School of Biosciences, University of Kent, Canterbury, UK.
  • Rose-Zerilli MJJ; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Institute for Life Sciences, University of Southampton, Southampton, UK.
Br J Oral Maxillofac Surg ; 62(2): 118-127, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38296711
ABSTRACT
Proliferative verrucous leukoplakia (PVL) is a rare oral potentially malignant disorder characterised by multifocal origin and unpredictable long-term evolution to oral squamous cell carcinoma (OSCC) or oral verrucous carcinoma (OVC). Currently no predictive biomarkers are in clinical use. We aimed to explore the genomic profile of PVL. A total of 685 cases in 26 studies were included in this review. Genomic data were presented in 15% of studies and biomarker analysis was reported in 85% of studies. At first clinical presentation, PVL is characterised by a high loss of heterozygosity (LOH), similar to OSCC, and low copy number alterations (CNA). As these progress, more CNAs and mutations in CDKN2A and alterations to ELAVL1 expression are noted, but no TP53 mutations are identified. There is significantly lower LOH at 17p in early PVL compared with OSCC (p = 0.037). Deletions in chromosomal loci 17q12, 5q31.1 and amplifications in 7q11.2, 7q22 are shared between early lesions and OVC. PVL shows CNAs at 11q31. WNT signalling pathway genes (SUZ12, CTTN and FOLR3) are enriched in CN-altered regions. PVL stroma shows significantly lower α-SMA and higher CD34 expression than OVC and OSCC. The exact genomic landscape is currently unclear, and further studies are necessary to unravel this mystery.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Boca / Carcinoma de Células Escamosas / Carcinoma Verrugoso / Neoplasias de Cabeza y Cuello Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Br J Oral Maxillofac Surg Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Boca / Carcinoma de Células Escamosas / Carcinoma Verrugoso / Neoplasias de Cabeza y Cuello Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Br J Oral Maxillofac Surg Año: 2024 Tipo del documento: Article